Patent details

Basic Information

Publication number:

LUC00169

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP181839689

Legal Status:

Inactive

Application number:

LUC00169

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/18/1334

Marketing Authorization Type:

Marketing Authorization Date:

22/11/2018

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Luxembourg (LU)

Dates

Filing date:

06/07/2020

First Marketing Authorization date:

22/11/2018

Grant date:

01/07/2024

Activation date:

Publication date:

06/07/2020

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

22/11/2033

SPC Extension Expiration:

22/11/2033

Rejection date:

Withdrawal date:

Owner

From:

06/07/2020

 

 

Name:

Melinta Therapeutics, Inc.

Address:

44 Whippany Road Suite 280, New Jersey 07960, Morristown, New Jersey, United States (US)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

06/07/2020

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Publication

Bulletin

1

Bulletin Heading:

SPC1

Bulletin edition number:

2020/09

Publication date:

04/08/2020

Description:

Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:

SPC2

Bulletin edition number:

2024/10

Publication date:

06/08/2024

Description:

Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:

01/09/2031

Annual Fee Number:

21

Annual Fee Amount:

410 Euro

Expected Payer:

Last Annual Fee Payment Date:

Last Annual Fee Paid Number:

Payer:

Filing date	Document type	Number of pages
06/07/2020	General Document	16
06/07/2020	General Document	3
06/07/2020	Application Form	4
06/07/2020	General Document	34
06/07/2020	Outgoing Correspondence	1
06/07/2020	Publication	1
01/07/2024	Publication	1
01/07/2024	Certificate	1
08/07/2024	Outgoing Correspondence	1